Project Grant R61CA309784
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $245K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $443,564 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 2, 2025, with completion by August 31, 2027. The award supports the development of a novel cancer immunotherapy platform utilizing engineered commensal skin bacteria to stimulate tumor-specific T cell immunity. The research focuses on leveraging Staphylococcus epidermidis, a naturally...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Broad Institute of MIT and Harvard a $795,544 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, with completion targeted for July 31, 2027. This award funds the development of computational methods for profiling the cancer virome and microbial strain genetics from shotgun metagenomes and metatranscriptomes. The deliverables include novel algorithms that integrate...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $742,382 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026 through May 31, 2031. The award supports preclinical research to investigate combination immunotherapy approaches for head and neck squamous cell carcinoma (HNSCC), a deadly malignancy with limited treatment options and poor response rates to current checkpoint...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $418,176.00 to Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) for the period September 1, 2025, through August 31, 2028. This three-year award supports the advanced development and validation of programmable nucleic acid cytometry, a technology designed to isolate and profile rare cell populations from tumors and tissues. Building on the...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Biology Research program (CFDA 93.396), awarded a $733,864 Project Grant to the Beckman Research Institute of the City of Hope, effective June 1, 2026 through May 31, 2031. The award funds fundamental research to identify and characterize stimulatory immune checkpoints that regulate macrophage-mediated programmed cell removal (PRCR), a critical process in tumor immunosurveillance and cancer elimination. Using...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $1.37 million to J. David Gladstone Institutes under the Cancer Biology Research program (CFDA 93.396) on August 1, 2025, through May 31, 2030. This project grant funds development of a spatial profiling-based immune hub perturbation platform designed to improve immunotherapy effectiveness in colorectal cancer (CRC). The research addresses a critical gap in preclinical models that can systematically evaluate candidate...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Dana-Farber Cancer Institute, Inc. a Project Grant of $718,275 under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026, through June 30, 2031. This award supports fundamental research investigating context-specific pathway dependencies of nuclear envelope (NE) proteins in brain cancer. The research employs a large-scale analysis framework called WEBSTER to assess how NE-associated proteins...
- Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $604,102 Project Grant to Harvard College's Office for Sponsored Programs effective May 1, 2026, through April 30, 2031. This award supports the development of a bioprinted three-dimensional (3D) vascular cancer model designed to advance understanding of T cell immunotherapy within solid tumors. The research deliverables include the creation of...
- Federal Grant Award Summary Award Overview: The National Cancer Institute (NCI) awarded Harvard Medical School a Project Grant of $237,023 on March 13, 2026, under the Cancer Biology Research program (CFDA 93.396) to support research through February 28, 2029. The award funds development of high-throughput technological tools to track the fate and dynamics of prematurely terminated transcripts in cancer cells, with performance conducted in Boston, Massachusetts. Research Deliverables: The...